The present invention provides 5'-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5'-carbon. These bicyclic nucleoside analogs are useful for enh
The present invention provides 5'-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5'-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.
대표청구항▼
What is claimed is: 1. A bicyclic nucleoside having the formula: wherein: Bx is a heterocyclic base moiety; one of T1 and T2 is H or a hydroxyl protecting group and the other of T1 and T2 is H, a hydroxyl protecting group or a reactive phosphorus group; Z is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alk
What is claimed is: 1. A bicyclic nucleoside having the formula: wherein: Bx is a heterocyclic base moiety; one of T1 and T2 is H or a hydroxyl protecting group and the other of T1 and T2 is H, a hydroxyl protecting group or a reactive phosphorus group; Z is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl, substituted C2-C6 alkynyl or substituted acyl (--C(═O)--); wherein each substituted group is mono or poly substituted with substituent groups independently selected from halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl, OJ1, SJ1, NJ1J2, N3, COOJ1, CN, O--C(═O)NJ1J2, N(H)C(═NH)NR1R2 or N(H)C(═X)N(H)J2 wherein X is O or S; and each J1 and J2 is, independently, H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl, C1-C6 aminoalkyl, substituted C1-C6 aminoalkyl or a protecting group. 2. The bicyclic nucleoside of claim 1 wherein Z is substituted C1-C6 alkyl. 3. The bicyclic nucleoside of claim 2 wherein Z is substituted methyl. 4. The bicyclic nucleoside of claim 3 wherein each of the substituent groups is, independently, F, NJ1J2, N3, CN, OJ1, SJ1, O--C(═O)NJ1J2, N(H)C(═NH)NJ1J2 or N(H)C(═O)N(H)J2. 5. The bicyclic nucleoside of claim 4 wherein each J1 and J2 is, independently H or C1-C6 alkyl. 6. The bicyclic nucleoside of claim 1 wherein Z is methyl, ethyl or methoxymethyl. 7. The bicyclic nucleoside of claim 6 wherein Z is methyl. 8. The bicyclic nucleoside of claim 1 wherein Z is ethenyl. 9. The bicyclic nucleoside of claim 1 wherein Z is substituted acyl. 10. The bicyclic nucleoside of claim 9 wherein Z is C(═O)NJ1J2. 11. The bicyclic nucleoside of claim 1 wherein at least one of T1 and T2 is a hydroxyl protecting group. 12. The bicyclic nucleoside of claim 11 wherein each of said hydroxyl protecting groups is, independently, selected from acetyl, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2-trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, benzoyl, p-phenylbenzoyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl (trityl), 4,4'-dimethoxytrityl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, triisopropylsilyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, 9-fluorenylmethyl carbonate, mesylate, tosylate, triflate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (MOX). 13. The bicyclic nucleoside of claim 11 wherein T1 is acetyl, benzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl or 4,4'-dimethoxytrityl. 14. The bicyclic nucleoside of claim 1 wherein T2 is a reactive phosphorus group. 15. The bicyclic nucleoside of claim 14 wherein the reactive phosphorus group is diisopropylcyanoethoxy phosphoramidite or H-phosphonate. 16. The bicyclic nucleoside of claim 15 wherein T2 is diisopropylcyanoethoxy phosphoramidite and T1 is 4,4'-dimethoxytrityl. 17. The bicyclic nucleoside of claim 1 having the configuration: 18. The bicyclic nucleoside of claim 1 having the configuration: 19. An oligomeric compound having at least one monomer of the formula: wherein Bx is a heterocyclic base moiety; T3 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; T4 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; Z is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl, substituted C2-C6 alkynyl or substituted acyl; wherein each substituted group is mono or poly substituted with substituent groups independently selected from halogen, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl, OJ1, SJ1, NJ1J2, N3, COOJ1, CN, O--C(═O)NJ1J2, N(H)C(═NH)NR1R2 or N(H)C(═X)N(H)J2 wherein X is O or S; each J1 and J2 is, independently, H, C1-C6 alkyl, substituted C1-C6 alkyl, C2-C6 alkenyl, substituted C2-C6 alkenyl, C2-C6 alkynyl, substituted C2-C6 alkynyl, C1-C6 aminoalkyl, substituted C1-C6 aminoalkyl or a protecting group; and wherein at least one of T3 and T4 is an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound. 20. The oligomeric compound of claim 19 wherein each Z is a substituted C1-C6 alkyl. 21. The oligomeric compound of claim 20 wherein each Z is substituted methyl. 22. The oligomeric compound of claim 21 wherein each of said substituent groups is, independently, F, NJ1J2, N3, CN, OJ1, SJ1, O--C(═O)NJ1J2, N(H)C(═NH)NJ1J2 or N(H)C(═O)N(H)J2. 23. The oligomeric compound of claim 22 wherein each J1 and J2 is, independently H or C1-C6 alkyl. 24. The oligomeric compound of claim 19 wherein each Z is methyl, ethyl or methoxymethyl. 25. The oligomeric compound of claim 24 wherein each Z is methyl. 26. The oligomeric compound of claim 19 wherein each Z is ethenyl. 27. The oligomeric compound of claim 19 wherein each Z is substituted acyl. 28. The oligomeric compound of claim 27 wherein each Z is C(═O)NJ1J2. 29. The oligomeric compound of claim 19 wherein one T3 is H or a hydroxyl protecting group. 30. The oligomeric compound of claim 19 wherein one T4 is H or a hydroxyl protecting group. 31. The oligomeric compound of claim 19 wherein at least one T3 is an internucleoside linking group attached to a nucleoside, a nucleotide or a monomeric subunit. 32. The oligomeric compound of claim 19 wherein at least one T4 is an internucleoside linking group attached to a nucleoside, a nucleotide or a monomeric subunit. 33. The oligomeric compound of claim 19 wherein at least one T3 is an internucleoside linking group attached to an oligonucleoside or an oligonucleotide. 34. The oligomeric compound of claim 19 wherein at least one T4 is an internucleoside linking group attached to an oligonucleoside or an oligonucleotide. 35. The oligomeric compound of claim 19 wherein at least one T3 is an internucleoside linking group attached to an oligomeric compound. 36. The oligomeric compound of claim 19 wherein at least one T4 is an internucleoside linking group attached to an oligomeric compound. 37. The oligomeric compound of claim 19 wherein at least one monomer has the configuration: 38. The oligomeric compound of claim 19 wherein at least one monomer has the configuration: 39. The oligomeric compound of claim 19 wherein at least one of T3 and T4 comprises an internucleoside linking group selected from phosphodiester or phosphorothioate. 40. The oligomeric compound of claim 19 wherein each internucleoside linking group is, independently, a phosphodiester or a phosphorothioate. 41. The oligomeric compound of claim 19 comprising at least one region of at least two contiguous monomers of said formula. 42. The oligomeric compound of claim 41 comprising at least two regions of at least two contiguous monomers of said formula. 43. The oligomeric compound of claim 42 comprising a gapped oligomeric compound. 44. The oligomeric compound of claim 19 comprising from about 8 to about 40 nucleosides and/or modified nucleosides or mimetics in length. 45. The oligomeric compound of claim 19 comprising from about 8 to about 20 nucleosides and/or modified nucleosides or mimetics in length. 46. The oligomeric compound of claim 19 comprising from about 10 to about 16 nucleosides and/or modified nucleosides or mimetics in length. 47. The oligomeric compound of claim 19 comprising from about 10 to about 14 nucleosides and/or modified nucleosides or mimetics in length. 48. A method of inhibiting gene expression comprising contacting one or more cells, a tissue or an animal with an oligomeric compound of claim 19. 49. The oligomeric compound of claim 19 wherein each monomer has the configuration: 50. The oligomeric compound of claim 19 wherein each monomer has the configuration:
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (122)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
Prakash, Thazha P.; Seth, Punit P.; Swayze, Eric E.; Bhanot, Sanjay; Freier, Susan M.; Bui, Huynh-Hoa, Compositions and methods for modulating growth hormone receptor expression.
Crooke, Rosanne M.; Graham, Mark J.; Freier, Susan M.; Lim, Marc; Dibble, Andrew, Methods and compositions for modulating apolipoprotein (a) expression.
Bennett, C. Frank; Freier, Susan M.; Rigo, Frank; Cleveland, Don W.; Lagier-Tourenne, Clotilde; Ravits, John M.; Baughn, Michael W., Methods for modulating C9ORF72 expression.
Bennett, C. Frank; Freier, Susan M.; Marcusson, Eric G.; Hsu, Ssucheng J.; MacLeod, Robert A., Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
Faghihi, Mohammad Ali; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.